{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-080021","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.799585+00:00","generated_at":"2026-05-31T23:49:39.566488+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PepGen appoints Afsaneh Mohebbi, Ph.D. as SVP Portfolio & Program Mgmt and Dave Borah, CFA as SVP IR & Corp Comms","bullets":["Afsaneh Mohebbi, Ph.D. appointed SVP, Portfolio & Program Management; previously consultant to PepGen since Jan 2024.","Dave Borah, CFA named SVP, Investor Relations & Corporate Communications; most recently SVP at Mural Oncology.","Appointments effective immediately; CEO cites expertise as key ahead of clinical milestones in H2 2024.","Mohebbi led Fabry drug Replagal and Firazyr approvals at Shire; Borah increased analyst coverage at Bicycle Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-080021","json":"https://secwatch.observer/filing/0000950170-24-080021.json","markdown":"https://secwatch.observer/filing/0000950170-24-080021.md","text":"https://secwatch.observer/filing/0000950170-24-080021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024080021/0000950170-24-080021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024080021/pepg-20240702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:49:39.566488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}